Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
BURLINGTON, Mass., April 25, 2017 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to provide an update on business operations and report its first-quarter 2017 financial results on Thursday, May 4, 2017, at 4:30 p.m. ET.
The dial-in number for the conference call is (855) 770-0022 for domestic participants and (908) 982-4677 for international participants, with Conference ID #11984746. A live webcast of the conference call can also be accessed through the “Investors” tab on the Flexion Therapeutics website. A webcast replay will be available online after the call.
About Flexion Therapeutics
Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA) of the knee. The company's lead product candidate, ZilrettaTM (also known as FX006) is being investigated for its potential to provide improved analgesia for the millions of U.S. patients who receive intra-articular injections for OA related knee pain annually.
Corporate Contact: Scott Young Sr. Director, Corporate Communications & Investor Relations Flexion Therapeutics, Inc. T: 781-305-7194 [email protected]
